This article was originally published in The Gray Sheet
Receives notification from FDA that its N-400 fetal oximeter is not substantially equivalent and will require a premarket approval application. A 510(k) for the device was submitted in September 1992. Nellcor "has requested a meeting with FDA officials to obtain clarification on the agency's position, and to define the steps required to file a PMA," the firm says. The device is designed to measure the oxygen content in fetal blood during delivery via "a sensor that is noninvasive to the fetus".
You may also be interested in...
COVID-19 Vaccines: ACIP’s Allocation Proposal Prioritizes Long-Term Care Residents, Essential Workers
First group to receive vaccine would comprise health care personnel and residents of long-term care facilities; next in line are non-health care essential workers, who would take priority over adults with high-risk medical conditions and those ages 65 years and older, according to the CDC advisory committee’s proposed allocation framework.
Azar says ACIP’s prioritization recommendations should carry weight, but states will be final arbiter of who is vaccinated.
Sanofi R&D head John Reed says the company has kept 95% of patients on its nearly 400 clinical trials, started 59 studies, and benefited from its in-house drug supply management.